- Home
- HIFS vs ZURA Comparison
HIFS vs ZURA Comparison
Compare HIFS & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIFS | ZURA |
|---|---|---|
| Founded | 1834 | 2022 |
| Country | United States | United States |
| Employees | 97 | 30 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 521.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HIFS | ZURA |
|---|---|---|
| Price | $289.55 | $6.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.78 |
| AVG Volume (30 Days) | 47.0K | ★ 514.5K |
| Earning Date | 01-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $209.71 | $0.99 |
| 52 Week High | $338.00 | $7.25 |
Technical Indicators
Market Signals| Indicator | HIFS | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 57.36 | 49.48 |
| Support Level | $286.81 | $5.49 |
| Resistance Level | $290.40 | $6.99 |
| Average True Range (ATR) | 9.57 | 0.49 |
| MACD | 2.99 | 0.00 |
| Stochastic Oscillator | 89.44 | 60.14 |
Price Performance
Historical ComparisonAbout HIFS Hingham Institution for Savings
Hingham Institution for Savings is a Massachusetts-chartered savings bank headquartered in Hingham, Massachusetts. The bank is principally engaged in the business of commercial and residential real estate mortgage lending, funded by a mix of retail and commercial deposits, wholesale deposits and borrowings. Its primary deposit products are savings, checking, and term certificate accounts, and its primary lending products are residential and commercial mortgage loans secured by properties in eastern Massachusetts. The bank also lends to commercial and residential real estate borrowers and services deposits for customers in the greater Washington, D.C. metropolitan area (WMA) and in the San Francisco Bay Area.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.